• E-mail :[email]
  • Phone : +33 540003432
  • Location : Bordeaux, France
Last update 2022-03-03 21:18:02.264

Cameron Mackereth PhD (Biochemistry)

Course and current status

from 12/2017 - Senior Scientist (Inserm DR2), Inserm unit U1212 (RNA: Natural and Artificial Regulation)

07/2011-11/2017 - Scientist (CR1), Inserm unit U1212 (RNA: Natural and Artificial Regulation)

from 09/2007 - Group Leader, Institut Européen de Chimie et Biologie, Pessac, France

08/2003-08/2007 - Postdoc, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany - group of Dr. Michael Sattler

09/1996-07/2003 - PhD (Biochemistry),  University of British Columbia, Canada - group of Dr. Lawrence McIntosh

09/1991-04/1996 - BSc (Biochemistry), University of Waterloo, Canada

01/1995-08/1995 and 04/1996-08/1996 - Research Assistant, Merck Frosst Centre for Therapeutic Research, Montreal, Canada

04/1994-08/1994 - Lab Technician, Wellesley Hospital Research Institute, Toronto, Canada

01/1993-04/1993 and 09/1993-12/1993 - Toxicology Evaluator, Health Canada – Pesticides Division, Ottawa, Canada

Scientific summary

Cameron Mackereth began his scientific training at the University of Waterloo, Waterloo, ON, Canada, where he completed a degree in biochemistry in 1996. His Ph.D. degree at the University of British Columbia, Vancouver, BC, Canada, under the supervision of Dr. Lawrence McIntosh, dealt with the structural investigation of a domain common to several protein families involved in transcription and cellular signaling. He continued to use nuclear magnetic resonance (NMR) spectroscopy at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, where he looked at domain arrangements of large protein-RNA splicing complexes in the group of Dr. Michael Sattler. In the fall of 2007, he joined the IECB as a Group Leader. The lab is focused on the structural details of how proteins and nucleic acids come together to form complexes. A combination of biochemical methods is used to probe the way in which the pieces of these biomolecules are assembled, but the main technique is nuclear magnetic resonance (NMR) spectroscopy. In July 2011 he was recruited as a scientist (CR1) in the French National Institute of Health and Medical Research (Inserm), and in 2017 became an Inserm senior scientist (DR2).

Image d’exemple